| Literature DB >> 30988315 |
William J Horton1, Matthew Jensen2, Aswathy Sebastian3, Craig A Praul3, Istvan Albert3,4, Paul A Bartell5,6,7.
Abstract
Many birds undertake long biannual voyages during the night. During these times of the year birds drastically reduce their amount of sleep, yet curiously perform as well on tests of physical and cognitive performance than during non-migrating times of the year. This inherent physiological protection disappears when birds are forced to stay awake at other times of the year; thus these protective changes are only associated with the nocturnal migratory state. The goal of the current study was to identify the physiological mechanisms that confer protection against the consequences of sleep loss while simultaneously allowing for the increased physical performance required for migration. We performed RNA-seq analyses of heart and liver collected from birds at different times of day under different migratory states and analyzed these data using differential expression, pathway analysis and WGCNA. We identified changes in gene expression networks implicating multiple systems and pathways. These pathways regulate many aspects of metabolism, immune function, wound repair, and protection of multiple organ systems. Consequently, the circannual program controlling the appearance of the migratory phenotype involves the complex regulation of diverse gene networks associated with the physical demands of migration.Entities:
Mesh:
Year: 2019 PMID: 30988315 PMCID: PMC6465361 DOI: 10.1038/s41598-019-41252-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Heatmap of Differentially Expressed Genes in the Heart and Liver. Heatmaps were generated with log2 expression of counts normalized to transcript size and million mapped reads (FPMK values). Differentially expressed genes (DEGs) are listed along the Y-axis in the order they clustered in to as indicated by the colored line along the Y-axis. Each column contains expression values for an individual bird, with groups indicated along the X-axis, and clustering indicated by the dendogram above the figure. Deeper red colors indicate higher expression while deeper blue indicates lower expression. Panel (a) shows DEGs found in the heart, and panel (b) shows DEG observed in the liver.
Top Differentially Expressed Genes in the Heart.
| Gene_Symbol | logFC | logCPM | F | PValue | FDR |
|---|---|---|---|---|---|
|
| |||||
| AKIP1 | −3.28E + 00 | 3.61E + 00 | 2.00E + 02 | 4.18E − 12 | 6.33E − 08 |
| CPT1A | −1.83E + 00 | 6.73E + 00 | 1.67E + 02 | 2.33E − 11 | 1.76E − 07 |
| FAM160B1 | −2.21E + 00 | 6.08E + 00 | 1.40E + 02 | 1.17E − 10 | 4.66E − 07 |
| C2H8orf22 | −2.71E + 00 | 4.00E + 00 | 1.39E + 02 | 1.23E − 10 | 4.66E − 07 |
| SLC43A2 | −2.50E + 00 | 6.08E + 00 | 1.34E + 02 | 1.75E − 10 | 5.30E − 07 |
| PER2 | 3.14E + 00 | 5.85E + 00 | 1.24E + 02 | 3.46E − 10 | 8.73E − 07 |
| CTSL | −2.35E + 00 | 8.23E + 00 | 1.21E + 02 | 4.42E − 10 | 9.55E − 07 |
| GTPBP2 | −1.27E + 00 | 5.67E + 00 | 1.18E + 02 | 5.43E − 10 | 1.03E − 06 |
| HSP90AA1 | 3.26E + 00 | 9.93E + 00 | 1.08E + 02 | 1.15E − 09 | 1.93E − 06 |
| HSP90B1 | 1.85E + 00 | 8.34E + 00 | 9.29E + 01 | 4.25E − 09 | 6.44E − 06 |
|
| |||||
| FAM160B1 | −1.89E + 00 | 6.08E + 00 | 1.04E + 02 | 1.56E − 09 | 2.37E − 05 |
| CTSL | −2.03E + 00 | 8.23E + 00 | 9.23E + 01 | 4.51E − 09 | 2.88E − 05 |
| LOC100229431 | 3.54E + 00 | 3.91E + 00 | 8.80E + 01 | 6.77E − 09 | 2.88E − 05 |
| OXSR1 | −1.13E + 00 | 6.79E + 00 | 8.68E + 01 | 7.61E − 09 | 2.88E − 05 |
| GABARAPL1 | −2.20E + 00 | 8.73E + 00 | 7.32E + 01 | 3.14E − 08 | 9.50E − 05 |
| ARHGAP20 | −1.27E + 00 | 5.96E + 00 | 6.53E + 01 | 7.82E − 08 | 1.97E − 04 |
| BNIP3 | −1.48E + 00 | 6.71E + 00 | 6.20E + 01 | 1.19E − 07 | 2.31E − 04 |
| HMCN1 | 1.94E + 00 | 4.09E + 00 | 6.18E + 01 | 1.22E − 07 | 2.31E − 04 |
| FREM2 | 3.02E + 00 | 5.74E + 00 | 6.07E + 01 | 1.39E − 07 | 2.34E − 04 |
| PNPLA8 | −9.50E-01 | 8.82E + 00 | 5.98E + 01 | 1.58E − 07 | 2.39E − 04 |
| CTSL | 2.23E + 00 | 8.23E + 00 | 5.83E + 01 | 1.92E − 07 | 1.72E − 03 |
| GABARAPL1 | 2.68E + 00 | 8.73E + 00 | 5.70E + 01 | 2.27E − 07 | 1.72E − 03 |
| FAM160B1 | 1.83E + 00 | 6.08E + 00 | 5.07E + 01 | 5.56E − 07 | 2.81E − 03 |
| NMRK2 | 2.44E + 00 | 5.23E + 00 | 4.76E + 01 | 8.90E − 07 | 3.37E − 03 |
| BNIP3 | 1.68E + 00 | 6.71E + 00 | 4.08E + 01 | 2.68E − 06 | 6.85E − 03 |
| TOB2 | 1.43E + 00 | 8.70E + 00 | 4.07E + 01 | 2.71E − 06 | 6.85E − 03 |
| SRF | 2.33E + 00 | 7.26E + 00 | 3.87E + 01 | 3.85E − 06 | 8.31E − 03 |
| FBXO32 | 1.93E + 00 | 8.07E + 00 | 3.77E + 01 | 4.60E − 06 | 8.71E − 03 |
| ALPK3 | 1.84E + 00 | 8.16E + 00 | 3.63E + 01 | 6.00E − 06 | 1.01E − 02 |
| EEF2K | −1.55E + 00 | 5.40E + 00 | 3.38E + 01 | 9.51E − 06 | 1.41E − 02 |
The top 10 differentially expressed genes for time of day, migratory status or the interaction in the heart are presented. Full lists of all differentially expressed genes can be found in Supplementary Table SI2. FC = fold change, CPM = counts per million mapped reads, FDR = corrected p-value.
Top Differentially Expressed Genes in the Liver.
| Gene | logFC | logCPM | F | PValue | FDR |
|---|---|---|---|---|---|
|
| |||||
| SCAP | 3.77E + 00 | 5.27E + 00 | 4.80E + 02 | 7.79E − 16 | 1.16E − 11 |
| PER2 | 5.11E + 00 | 5.35E + 00 | 4.01E + 02 | 4.64E − 15 | 3.45E − 11 |
| CTSL | −3.92E + 00 | 9.94E + 00 | 3.12E + 02 | 5.48E − 14 | 2.72E − 10 |
| SLC43A2 | −4.05E + 00 | 7.55E + 00 | 2.57E + 02 | 3.53E − 13 | 1.31E − 09 |
| LOC100229295 | −2.74E + 00 | 8.30E + 00 | 2.40E + 02 | 6.84E − 13 | 2.00E − 09 |
| CHD2 | 2.23E + 00 | 7.20E + 00 | 2.36E + 02 | 8.21E − 13 | 2.00E − 09 |
| SLC22A5 | −3.27E + 00 | 7.37E + 00 | 2.30E + 02 | 1.02E − 12 | 2.18E − 09 |
| HAL | −3.24E + 00 | 9.59E + 00 | 2.05E + 02 | 3.16E − 12 | 5.88E − 09 |
| CITED2 | −2.82E + 00 | 5.16E + 00 | 1.95E + 02 | 4.93E − 12 | 8.00E − 09 |
| IVNS1ABP | −4.04E + 00 | 1.01E + 01 | 1.94E + 02 | 5.35E − 12 | 8.00E − 09 |
|
| |||||
| SLC26A5 | 2.86E + 00 | 8.59E + 00 | 5.95E + 01 | 1.58E − 07 | 2.36E − 03 |
| UPP2 | −3.14E + 00 | 5.75E + 00 | 5.36E + 01 | 3.52E − 07 | 2.61E − 03 |
| LOC100223441 | 1.26E + 00 | 8.55E + 00 | 4.78E + 01 | 8.31E − 07 | 2.67E − 03 |
| LOC100225830 | 1.60E + 00 | 5.87E + 00 | 4.74E + 01 | 8.86E − 07 | 2.67E − 03 |
| LOC100220148 | 3.74E + 00 | 7.60E + 00 | 4.71E + 01 | 9.31E − 07 | 2.67E − 03 |
| UPP1 | −3.23E + 00 | 5.13E + 00 | 4.62E + 01 | 1.08E − 06 | 2.67E − 03 |
| LOC100221560 | 5.48E + 00 | 3.79E + 00 | 4.49E + 01 | 1.31E − 06 | 2.70E − 03 |
| TDO2 | −1.32E + 00 | 9.60E + 00 | 4.43E + 01 | 1.45E − 06 | 2.70E − 03 |
| TTR | 6.85E + 00 | 1.03E + 01 | 4.25E + 01 | 1.96E − 06 | 3.24E − 03 |
| AK4 | −1.98E + 00 | 4.02E + 00 | 3.68E + 01 | 5.35E − 06 | 7.95E − 03 |
| UPP2 | 4.15E + 00 | 5.75E + 00 | 5.25E + 01 | 4.16E − 07 | 6.18E − 03 |
| UPP1 | 4.25E + 00 | 5.13E + 00 | 4.59E + 01 | 1.13E − 06 | 8.39E − 03 |
| SCAP | −1.55E + 00 | 5.27E + 00 | 4.93E + 01 | 2.10E − 06 | 1.04E − 02 |
| PCK1 | 5.79E + 00 | 1.18E + 01 | 3.69E + 01 | 5.27E − 06 | 1.96E − 02 |
| RXRG | −1.72E + 00 | 4.47E + 00 | 2.83E + 01 | 2.90E − 05 | 8.62E − 02 |
| TAT | 1.67E + 00 | 1.09E + 01 | 2.73E + 01 | 3.67E − 05 | 9.09E − 02 |
| IRS4 | 1.24E + 00 | 6.94E + 00 | 2.85E + 01 | 5.00E − 05 | 1.06E-01 |
| FABP7 | −1.56E + 00 | 9.29E + 00 | 2.50E + 01 | 6.15E − 05 | 1.14E − 01 |
| GGACT | −1.73E + 00 | 5.87E + 00 | 2.31E + 01 | 9.85E − 05 | 1.52E − 01 |
| CDO1 | 1.47E + 00 | 1.09E + 01 | 2.29E + 01 | 1.02E − 04 | 1.52E − 01 |
The top 10 differentially expressed genes in the liver for each statistical effect are shown in this table. The complete list of all genes can be found in Supplementary Table SI3. FC = fold change, CPM = counts per million mapped reads, FDR = corrected p-value.
Top IPA Pathway Enrichment for DEGs in Heart.
| Ingenuity Canonical Pathways | −log (p-value) | Ratio | z-score | Molecules |
|---|---|---|---|---|
|
| ||||
| Unfolded protein response | 5.21E00 | 9.26E-02 | NaN | HSPA8, HSP90B1, INSIG1, HSPH1, CEBPB |
| Mitochondrial L-carnitine Shuttle Pathway | 2.34E00 | 9.52E-02 | NaN | CPT1A, ACSBG2 |
| eNOS Signaling | 2.17E00 | 2.58E-02 | NaN | HSPA8, AQP9, HSP90B1, HSP90AA1 |
| Aldosterone Signaling in Epithelial Cells | 2.1E00 | 2.47E-02 | NaN | HSPA8, HSP90B1, HSPH1, HSP90AA1 |
| Glucocorticoid Receptor Signaling | 1.93E00 | 1.78E-02 | NaN | HSPA8, HSP90B1, HSP90AA1, PCK1, CEBPB |
|
| ||||
| T Cell Receptor Signaling | 8.71E00 | 1.18E-01 | NaN | PTPRC, CD247, CD28, PTPN7, TXK, CARD11, RASGRP1, ZAP70, PIK3CD, CD8B, LCP2, ITK |
| iCOS-iCOSL Signaling in T Helper Cells | 8.19E00 | 1.06E-01 | 2.714 | PTPRC, CD247, CD28, CD40LG, IL2RG, CD80, ZAP70, PIK3CD, INPP5D, LCP2, IL2RB, ITK |
| Complement System | 5.38E00 | 1.58E-01 | 1.000 | ITGB2, C1QC, C1QA, C1QB, CFH, C3AR1 |
| CD28 Signaling in T Helper Cells | 4.93E00 | 7.32E-02 | 2.828 | PTPRC, CD247, CD28, CD80, CARD11, ZAP70, PIK3CD, LCP2, ITK |
| Leukocyte Extravasation Signaling | 4.64E00 | 5.39E-02 | 3.317 | ITGB2, SRC, NCF1, TXK, CXCR4, RASGRP1, CXCL12, PIK3CD, NCF4, ITGA4, ITK |
| p38 MAPK Signaling | 3.24E00 | 2.56E-02 | NaN | SRF, PLA2G4F, EEF2K |
| Phospholipases | 2.39E00 | 2.94E-02 | NaN | HMOX1, PLA2G4F |
| Phospholipase C Signaling | 2.32E00 | 1.22E-02 | NaN | HMOX1, HDAC9, PLA2G4F |
| PDGF Signaling | 2.22E00 | 2.41E-02 | NaN | SRF, CAV3 |
| p53 Signaling | 2.08E00 | 2.04E-02 | NaN | HDAC9, GADD45B |
Top 5 enriched pathways in the heart as determined with IPA for differentially expressed genes. Full IPA pathway enrichment lists can be found in Supplementary Information Table SI4. The −log (p-value) indicates that the molecules listed lead to pathway enrichment over expected, and ratio and z-score indicate directionality of the pathway activity.
Top IPA Pathway Enrichment for DEGs in Liver.
| Ingenuity Canonical Pathways | −log (p-value) | Ratio | z-score | Molecules |
|---|---|---|---|---|
|
| ||||
| TR/RXR Activation | 4.48E00 | 9.78E-02 | NaN | PIK3R3, RXRG, ADRB1, COL6A3, NXPH2, NCOR2, PCK1, ME1, RCAN2 |
| Ketogenesis | 3.64E00 | 2.22E-01 | NaN | BDH1, HMGCLL1, HMGCL, HMGCS1 |
| Circadian Rhythm Signaling | 3.48E00 | 1.43E-01 | NaN | PER3, GRIN2B, BHLHE41, CRY1, PER2 |
| Amyotrophic Lateral Sclerosis Signaling | 2.56E00 | 6.54E-02 | NaN | PIK3R3, GRIN2B, CAPN6, CACNA1D, GRIA1, GRID1, GLUL |
| Mitochondrial L-carnitine Shuttle Pathway | 2.26E00 | 1.43E-01 | NaN | CPT1A, ACSL5, ACSBG2 |
|
| ||||
| Salvage Pathways of Pyrimidine Ribonucleotides | 6.09E00 | 6.42E-02 | NaN | UPP2, UPP1, AK4, PLK1, TTK, NEK2, CDK1 |
| Cell Cycle: G2/M DNA Damage Checkpoint Regulation | 5.48E00 | 1.02E-01 | −2.000 | CKS2, TOP2A, CCNB2, PLK1, CDK1 |
| Mitotic Roles of Polo-Like Kinase | 4.83E00 | 7.58E-02 | 2.236 | KIF23, CDC20, CCNB2, PLK1, CDK1 |
| Pyridoxal 5′-phosphate Salvage Pathway | 3.39E00 | 5.41E-02 | NaN | PLK1, TTK, NEK2, CDK1 |
| Role of BRCA1 in DNA Damage Response | 3.3E00 | 5.13E-02 | 1.000 | FANCG, RBBP8, PLK1, FANCC |
| TR/RXR Activation | 3.6E00 | 2.17E-02 | NaN | RXRG, PCK1 |
| Salvage Pathways of Pyrimidine Ribonucleotides | 3.45E00 | 1.83E-02 | NaN | UPP2, UPP1 |
| 4-hydroxyphenylpyruvate Biosynthesis | 2.87E00 | 2E-01 | NaN | TAT |
| Glucocorticoid Receptor Signaling | 2.63E00 | 7.12E-03 | NaN | TAT, PCK1 |
| Tyrosine Degradation I | 2.42E00 | 7.14E-02 | NaN | TAT |
Top 5 enriched pathways in the liver as determined with IPA performed only on differentially expressed genes from EdgeR. Full IPA pathway enrichment lists can be found in Supplementary Information Table SI4. The listed molecules lead to the significance scores for pathway enrichment, while ratio and z-scores indicate pathway activity.
Figure 2Selected WGCNA Modules. Eigengene expression for modules 5 (panel a) and 10 (panel b) from the liver, and modules 35 (c) and 14 (d) from the heart using WGCNA analysis. Non-migratory groups are indicated in monochrome and migratory groups are in blue. Lighter bars (I.E. white and light blue) indicate ZT06 while darker bars (I.E. black and dark blue) indicate ZT18. Modules 5 and 10 from the liver are both significant for main effects of time and migratory status, while modules 35 and 14 show significant main effects of migratory status. Module 35 also shows a significant time by migratory status interaction.
IPA Pathway Enrichment for Selected WGCNA Modules.
| Ingenuity Canonical Pathways | −log (B-H p-value) | Ratio | z-score | Molecules |
|---|---|---|---|---|
|
| ||||
| Protein Ubiquitination Pathway | 6.29 | 0.07 | NEDD4, PSMA6, UBE4B, CUL1, DNAJC3, HSPA5, DNAJA1, SKP2, HSPA8, PSMD11, HSP90B1, PSMC1, PSMC6, USP47, PSMB1, HSP90AA1, PSMD1, USP37, PSMC3 | |
| Unfolded protein response | 2.92 | 0.13 | HSPA8, SCAP, HSP90B1, DNAJC3, CANX, DNAJA2, HSPA5 | |
| Aldosterone Signaling in Epithelial Cells | 2.8 | 0.07 | −1.342 | HSPA8, HSP90B1, NEDD4, PDIA3, PRKCD, DNAJC3, HSP90AA1, IRS2, ITPR1, DNAJA1, HSPA5 |
| Tryptophan Degradation III (Eukaryotic) | 1.88 | 0.19 | ACMSD, L3HYPDH, HADH, KYNU | |
| Ketogenesis | 1.75 | 0.3 | BDH1, HMGCL, HMGCS1 | |
|
| ||||
| Stearate Biosynthesis I (Animals) | 1.9 | 0.11 | DHCR24, PPT1, ACSL5, ELOVL6 | |
| Tryptophan Degradation III (Eukaryotic) | 1.55 | 0.14 | TDO2, HAAO, ACAT1 | |
| Superpathway of Cholesterol Biosynthesis | 1.35 | 0.11 | DHCR24, ACAT1, LBR | |
|
| ||||
| IL-6 Signaling | 1.87 | 0.03 | 1 | CSNK2A2, SRF, MAP3K7, PIK3R4 |
| EGF Signaling | 1.66 | 0.04 | CSNK2A2, SRF, PIK3R4 | |
| LPS-stimulated MAPK Signaling | 1.61 | 0.03 | SRF, MAP3K7, PIK3R4 | |
| PDGF Signaling | 1.61 | 0.03 | CSNK2A2, SRF, PIK3R4 | |
| IGF-1 Signaling | 1.5 | 0.03 | CSNK2A2, SRF, PIK3R4 | |
|
| ||||
| Signaling by Rho Family GTPases | 3.5 | 0.06 | −3.051 | GNB4, ACTR2, SEPT8, ACTR3, CDC42, CYFIP1, RHOA, GNA12, SEPT7, ARPC5, VIM, IRS2, ARHGEF3, ARHGEF10, SEPT2 |
| RhoA Signaling | 3.22 | 0.08 | −2.828 | SEPT8, ACTR2, ACTR3, ABL2, GNA12, RHOA, ARPC5, SEPT7, SEMA3F, SEPT2 |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 3.22 | 0.07 | COL5A2, COL4A1, COL6A1, MYH9, COL6A3, COL6A2, IFNGR1, MMP2, IFNAR2, PDGFB, PDGFRB, BCL2 | |
| Axonal Guidance Signaling | 3.21 | 0.04 | ACTR2, FYN, GNA12, ARPC5, MMP2, PLXND1, PDGFB, GNB4, SEMA3A, ACTR3, CDC42, RHOA, ADAM10, PLXNB2, IRS2, PRKD3, SEMA3F, PLCD4, NRP1 | |
| Rac Signaling | 2.8 | 0.08 | −2.121 | ACTR2, ACTR3, CDC42, CYFIP1, RHOA, ARPC5, MAP3K1, IRS2, NCKAP1 |
| Integrin Signaling | 2.74 | 0.05 | −2.714 | FYN, ACTR2, ACTR3, CDC42, RHOA, RALB, ARPC5, ITGAV, IRS2, ITGA1, TSPAN4, PDGFB |
| Actin Cytoskeleton Signaling | 2.64 | 0.05 | −2.333 | ACTR2, ACTR3, MYH9, CDC42, CYFIP1, GNA12, RHOA, ARPC5, IRS2, TMSB10/TMSB4X, PDGFB, NCKAP1 |
| Actin Nucleation by ARP-WASP Complex | 2.43 | 0.11 | −2.449 | ACTR2, ACTR3, CDC42, GNA12, RHOA, ARPC5 |
| Ephrin Receptor Signaling | 2.43 | 0.06 | −2.646 | FYN, ACTR2, GNB4, ACTR3, CDC42, GNA12, RHOA, ARPC5, ADAM10, PDGFB |
| Molecular Mechanisms of Cancer | 2.37 | 0.04 | FYN, GNA12, RALB, CDK6, BCL2, CCND2, CDC42, RHOA, IRS2, CFLAR, ARHGEF3, CTNNB1, ARHGEF10, PRKD3, BIRC2 | |
| PDGF Signaling | 2.28 | 0.08 | 0.378 | ABL2, INPP5J, MAP3K1, IRS2, OCRL, PDGFB, PDGFRB |
| Sphingosine-1-phosphate Signaling | 2.28 | 0.07 | −0.378 | GNA12, CASP2, RHOA, IRS2, PLCD4, PDGFB, ASAH1, PDGFRB |
| Death Receptor Signaling | 2.28 | 0.08 | 0.378 | RIPK1, TIPARP, CASP2, CFLAR, PARP14, BCL2, BIRC2 |
| Fcγ Receptor-mediated Phagocytosis in Macrophages and Monocytes | 2.28 | 0.08 | −2.646 | FYN, ACTR2, YES1, ACTR3, CDC42, ARPC5, PRKD3 |
| TNFR1 Signaling | 2.01 | 0.1 | −1.342 | RIPK1, CDC42, CASP2, MAP3K1, BIRC2 |
| RhoGDI Signaling | 2.01 | 0.05 | 2.646 | ACTR2, GNB4, ACTR3, CDC42, GNA12, RHOA, ARPC5, ARHGEF3, ARHGEF10 |
| Epithelial Adherens Junction Signaling | 1.87 | 0.05 | ACTR2, YES1, ACTR3, MYH9, CDC42, RHOA, ARPC5, CTNNB1 | |
| NF-κB Activation by Viruses | 1.76 | 0.07 | RIPK1, MAP3K1, ITGAV, IRS2, ITGA1, PRKD3 | |
| PTEN Signaling | 1.76 | 0.06 | 1.89 | INPP5J, CDC42, FOXO3, PREX2, OCRL, PDGFRB, BCL2 |
| fMLP Signaling in Neutrophils | 1.76 | 0.06 | −1.633 | ACTR2, GNB4, ACTR3, CDC42, ARPC5, IRS2, PRKD3 |
| Ephrin A Signaling | 1.76 | 0.08 | FYN, CDC42, RHOA, ADAM10, IRS2 | |
| IL-8 Signaling | 1.76 | 0.05 | −2.121 | GNB4, CCND2, GNA12, RHOA, ITGAV, IRS2, MMP2, PRKD3, BCL2 |
| Glioblastoma Multiforme Signaling | 1.76 | 0.05 | −1.134 | CDC42, RHOA, CDK6, IRS2, CTNNB1, PLCD4, PDGFB, PDGFRB |
| PI3K/AKT Signaling | 1.76 | 0.06 | −2.449 | YWHAQ, INPP5J, FOXO3, YWHAZ, CTNNB1, OCRL, BCL2 |
| Reelin Signaling in Neurons | 1.75 | 0.07 | FYN, YES1, IRS2, ITGA1, ARHGEF3, ARHGEF10 | |
| ERK5 Signaling | 1.74 | 0.08 | YWHAQ, IL6ST, GNA12, FOXO3, YWHAZ | |
| D-myo-inositol (1,4,5)-trisphosphate Degradation | 1.7 | 0.17 | IMPAD1, INPP5J, OCRL | |
| CD28 Signaling in T Helper Cells | 1.69 | 0.05 | −1.89 | FYN, ACTR2, ACTR3, CDC42, ARPC5, MAP3K1, IRS2 |
| Leukocyte Extravasation Signaling | 1.67 | 0.04 | −2.121 | CD99, CDC42, RHOA, PECAM1, IRS2, ITGA1, MMP2, CTNNB1, PRKD3 |
| Ephrin B Signaling | 1.52 | 0.07 | GNB4, CDC42, GNA12, RHOA, CTNNB1 | |
| HGF Signaling | 1.38 | 0.05 | −1 | ETS1, CDC42, MAP3K1, IRS2, PRKD3, ELK3 |
| Phospholipase C Signaling | 1.38 | 0.04 | FYN, GNB4, MARCKS, HDAC4, RHOA, RALB, ARHGEF3, PRKD3, ARHGEF10 | |
| Superpathway of D-myo-inositol (1,4,5)-trisphosphate Metabolism | 1.38 | 0.12 | IMPAD1, INPP5J, OCRL | |
| Macropinocytosis Signaling | 1.38 | 0.06 | CDC42, RHOA, IRS2, PRKD3, PDGFB | |
| ILK Signaling | 1.38 | 0.04 | −1.633 | MYH9, LIMS2, CDC42, RHOA, VIM, IRS2, TMSB10/TMSB4X, CTNNB1 |
| Inositol Pyrophosphates Biosynthesis | 1.36 | 0.25 | IP6K1, PPIP5K2 | |
| Semaphorin Signaling in Neurons | 1.35 | 0.08 | FYN, SEMA3A, RHOA, NRP1 | |
| Thrombin Signaling | 1.35 | 0.04 | −1.134 | GNB4, GNA12, RHOA, IRS2, ARHGEF3, PRKD3, ARHGEF10, PLCD4 |
| Protein Kinase A Signaling | 1.35 | 0.03 | 0 | YWHAQ, GNB4, PTPRG, RHOA, MAP3K1, YWHAZ, AKAP6, PDE4D, CTNNB1, PRKD3, PLCD4, PHKG1 |
| Role of Tissue Factor in Cancer | 1.35 | 0.05 | FYN, YES1, CDC42, GNA12, ITGAV, IRS2 | |
| phagosome formation | 1.35 | 0.05 | MARCKS, RHOA, PLA2R1, IRS2, PRKD3, PLCD4 | |
| HER-2 Signaling in Breast Cancer | 1.31 | 0.06 | CDC42, CDK6, IRS2, MMP2, PRKD3 | |
Pathway enrichment scores and contributing genes from each of the four selected WGCNA modules (5 and 10 from the liver and 35 and 14 from the heart) are presented. Full tables for all modules can be found in Supplementary Materials Fig. S6 (heart) and S7 (liver).